Sophia Genetics announces collaboration with MSK Cancer Center and AstraZeneca

Sophia Genetics (SOPH) announced a collaboration with Memorial Sloan Kettering Cancer Center, or MSK, a top cancer treatment and research institution, and AstraZeneca (AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide. The partnership will provide MSK’s proprietary liquid biopsy and solid tumor cancer tests – MSK-ACCESS and MSK-IMPACT- to organizations via the decentralized, technology-agnostic SOPHiA DDM Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca’s global footprint. Through SOPHiA GENETICS’ cloud-based platform, which provides highly accurate and reliable data and insights, institutions around the world – and in traditionally under-resourced and under-served areas – will have the power to make data-driven decisions.